Illumina Inc. Stock
€140.78
Your prediction
Illumina Inc. Stock
Pros and Cons of Illumina Inc. in the next few years
Pros
Cons
Performance of Illumina Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | -3.400% | 0.744% | 18.402% | 95.718% | 23.189% | -28.400% | -59.040% |
| Veeva Systems A | -2.570% | 0.234% | 2.322% | -40.907% | -21.775% | -17.054% | -36.793% |
| Thermo Fisher Scientific Inc. | -1.420% | -2.865% | 2.781% | 17.789% | -16.997% | -15.248% | 11.195% |
| Boston Scientific | 0.130% | 1.690% | -11.963% | -53.189% | -48.243% | -12.211% | 21.975% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Given a brief glance, Illumina with the US symbol (ILMN) seemingly presents an interesting financial scenario. There exist varied factors in the financials that catch attention, while certain aspects bespeak areas the company needs to address. However, it is important to delve deeper into the data for a comprehensive understanding.
The gross profit as per the Trailing Twelve Months (TTM) indicates a prospect reassuringly. The GrossProfitTTM is 3145000000, referring to overall revenue's percentage that the company retains after direct costs associated with making the products have been considered. Maintaining a healthy gross margin suggests productive internal cost management and pricing policies compared to competitors.
In terms of the company's market appeal indicated by the Price-to-Sales (PriceSalesTTM: 6.6241) and Price-to-Book (PriceBookMRQ: 4.8854) ratios. Both are less than the commonly used threshold of 10 for overvalued prospects, indicating a potentially undervalued situation assuming sustained performance. Thus, for investors keen on value investing, Illumina could be an interesting opportunity.
Comments
News
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
Grail's (NASDAQ: GRAL) stock closed at a record high of $116.06 in January. That marked a 732% gain from its $13.95 opening price following its spin-off from Illumina (NASDAQ: ILMN) in June 2024
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
Key Points
- Interested in GRAIL, Inc.? Here are five stocks we like better.
- GRAIL said its Galleri blood test showed it can shift cancer detection earlier and cut stage 4 diagnoses, with the
This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street
Grail (NASDAQ: GRAL), a developer of multi-cancer early detection (MCED) tests, was spun off from Illumina (NASDAQ: ILMN) in June 2024. Its stock started trading at $13.95 per share, set a record